WASHINGTON / RankWire.AI / – A distinctive inherited genetic alteration dramatically increases an individual’s overall likelihood of developing lung cancer by approximately 25 times, with non-smokers facing an elevated risk of about 60 times, according to a recent publication in the journal Science. The study, a collaborative effort between researchers at the Dana-Farber Cancer Institute and the 23andMe Research Institute, analyzed anonymized genomic data from over 3.3 million people. The team pinpointed the germline variant, known as EGFR T790M, as one of the most potent inherited genetic factors linked to lung cancer identified so far.
This mutation resides in the epidermal growth factor receptor gene, which plays a key role in controlling cell growth and division within lung tissue. While somatic mutations in the EGFR gene acquired during life are established drivers of non-small cell lung cancer, the T790M germline mutation is inherited from birth and found in all cells. Data from the National Cancer Institute indicates that this mutation occurs in about 1 in every 15,850 individuals in the United States. Lead author Dr. Jaclyn LoPiccolo highlighted that carriers have roughly a 62-fold increased risk of lung cancer if they are non-smokers, compared to about an 11-fold increase for those with a history of smoking.
Genetic lineage analysis revealed that the EGFR T790M mutation is disproportionately common among populations in Southern Appalachia, specifically in Tennessee and Alabama. Evolutionary geneticists traced the origin of the mutation to British and Irish settlers who migrated to North America during colonial times, with the mutation becoming more prevalent following a bottleneck event roughly 200 years ago. Dr. Pasi A. Jänne, senior author of the study, emphasized that while lung cancer screening primarily focuses on tobacco exposure, the discovery of significant genetic risk factors could lead to targeted low-dose CT screening for non-smoking carriers.
Dana-Farber Study Analyzes Over 3.3 Million Genomes to Assess Genetic Risk
Supported by the National Institutes of Health, the research confirmed that the mutation is strongly associated with lung cancer, showing no significant correlation with 17 other common cancers evaluated in the dataset. Oncologists noted that, although tobacco remains the primary cause of lung cancer, the incidence of non-smoking-related lung cancer is increasingly recognized as a global health concern. Several pharmaceutical companies, including AstraZeneca, are actively developing targeted tyrosine kinase inhibitors like Tagrisso to treat EGFR-mutated lung tumors when they become advanced.
Co-senior author Dr. Alexander Gusev pointed out that the study exemplifies how a single inherited point mutation can have an outsized impact on disease risk. Medical experts advise individuals with multiple family members affected by lung cancer, unexplained multifocal lung nodules, or ancestral ties to Southern Appalachia to consult genetic counselors. Researchers underline that possessing the mutation does not guarantee lung cancer development, as environmental factors and additional genetic changes also influence whether malignant transformation occurs over time.
EGFR Gene’s Role in Cellular Growth Regulation and Cancer Susceptibility
The research team intends to expand their observational efforts through the ongoing INHERIT Study, focusing on additional inherited EGFR variants across diverse racial groups. Long-term monitoring aims to identify environmental triggers and secondary genetic alterations that explain why some carriers develop tumors while others remain unaffected.
Findings related to population genetics, risk assessments, and screening strategies are available via peer-reviewed medical repositories and institutional announcement portals. Updated biomarker data will be presented by clinical researchers at upcoming international oncology conferences to guide future screening protocols.